These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Intermittent Subcutaneous Injections of Apomorphine in Parkinson's Disease. Ceylan M; Gültekin M; Durmaz Çelik N; Samanci B; Yalçin Çakmakli G; Yilmaz R Eurasian J Med; 2022 Dec; 54(Suppl1):71-76. PubMed ID: 36655449 [TBL] [Abstract][Full Text] [Related]
3. Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson's disease. Nasser A; Gomeni R; Ceresoli-Borroni G; Xie L; Busse GD; Melyan Z; Rubin J J Pharmacokinet Pharmacodyn; 2024 May; ():. PubMed ID: 38816542 [No Abstract] [Full Text] [Related]
4. A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease. Dewey RB; Maraganore DM; Ahlskog JE; Matsumoto JY Mov Disord; 1998 Sep; 13(5):782-7. PubMed ID: 9756146 [TBL] [Abstract][Full Text] [Related]
5. Intermittent Apomorphine Use for off Period Rescue in Parkinson's Disease: A Pragmatic Review of over Three Decades of Clinical Experience. Castillo-Torres SA; Lees AJ; Merello M Mov Disord Clin Pract; 2023 Feb; 10(2):190-208. PubMed ID: 36825043 [TBL] [Abstract][Full Text] [Related]
6. Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations. Carbone F; Djamshidian A; Seppi K; Poewe W CNS Drugs; 2019 Sep; 33(9):905-918. PubMed ID: 31473980 [TBL] [Abstract][Full Text] [Related]
8. Dystonia in Parkinson's disease. Tolosa E; Compta Y J Neurol; 2006 Dec; 253 Suppl 7():VII7-13. PubMed ID: 17131231 [TBL] [Abstract][Full Text] [Related]
9. [Apomorphine in the treatment of Parkinson's Disease]. Dressler D Nervenarzt; 2005 Jun; 76(6):681-9. PubMed ID: 15592807 [TBL] [Abstract][Full Text] [Related]
10. Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma? Dépatie L; Lal S J Psychiatry Neurosci; 2001 May; 26(3):203-20. PubMed ID: 11394190 [TBL] [Abstract][Full Text] [Related]
11. [Apomorphine for treatment of "off-periods" in Parkinson's disease]. Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339 [TBL] [Abstract][Full Text] [Related]
12. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329 [TBL] [Abstract][Full Text] [Related]
13. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease. Deleu D; Hanssens Y; Northway MG Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576 [TBL] [Abstract][Full Text] [Related]
14. [Apomorphine: an alternative in the control of motor fluctuations in Parkinson's disease]. Ferraz HB; Azevedo-Silva SM; Borges V; Rocha MS; Andrade LA Arq Neuropsiquiatr; 1995 Jun; 53(2):245-51. PubMed ID: 7487531 [TBL] [Abstract][Full Text] [Related]
15. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease. Chen JJ; Obering C Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444 [TBL] [Abstract][Full Text] [Related]
16. Long-term treatment with intermitent intranasal or subcutaneous apormorphine in patients with levodopa-related motor fluctuations. Esteban Muñoz J; Martí MJ; Marín C; Tolosa E Clin Neuropharmacol; 1997 Jun; 20(3):245-52. PubMed ID: 9197948 [TBL] [Abstract][Full Text] [Related]